title: A novel recombinant Salmonella vaccine enhances the innate immunity of NK cells against acute myeloid leukaemia cells Kasumi-1 in vitro.
abstract: Minor histocompatibility antigen HA-1-specific cytotoxic lymphocyte (CTL) clones have apparent anti-leukaemic efficacy, and the AML/ETO gene is a special fusion gene in leukaemic cells. Thus, we hypothesised that a vaccine targeting HA-1 and AML/ETO could stimulate NK cells to target leukaemia cells. Furthermore, we packaged the vaccine using attenuated Salmonella to enhance its immuno-activity. Expression of the NK cell-activating ligand ULBP2 was notably elevated upon packaging in a co-recombinant group. An AML/ETO single plasmid gave the weakest vaccine. The level of miR-182, which targets ULBP2, significantly decreased with increasing IFN-γ and granzyme B in a co-recombinant group. In summary, DNA vaccines including AML/ETO and HA-1 fragments significantly enhance the innate immunity of NK cells in vitro.
authors: Department of Oncology, The Sixth People's Hospital of Shanghai, Shanghai Jiao Tong University, Shanghai, China; School of Life Sciences, Sun Yat-Sen University, Guangzhou, China.
authors: Bei
authors: B
authors: Zhang
authors: Yuan
authors: Y
authors: Liu
authors: Xiuju
authors: X
authors: Wang
authors: Ling
authors: L
authors: Jiang
authors: Zhigang
authors: Z
authors: Lu
authors: Xing
authors: X
authors: Zhang
authors: Kunpeng
authors: K
authors: Li
authors: Haiyan
authors: H
authors: Hu
mesh_terms: D017209:Apoptosis; D001428:Bacterial Vaccines / Q000276:immunology*; D002478:Cells, Cultured; D058851:GPI-Linked Proteins / Q000235:genetics / Q000378:metabolism; D053804:Granzymes / Q000378:metabolism; D057809:HEK293 Cells; D006801:Humans; D007113:Immunity, Innate; D036341:Intercellular Signaling Peptides and Proteins / Q000235:genetics / Q000378:metabolism; D007371:Interferon-gamma / Q000378:metabolism; D007694:Killer Cells, Natural / Q000166:cytology / Q000276:immunology* / Q000378:metabolism; D015470:Leukemia, Myeloid, Acute / Q000276:immunology / Q000473:pathology; D035683:MicroRNAs / Q000378:metabolism; D015778:Minor Histocompatibility Antigens / Q000235:genetics / Q000378:metabolism; D009842:Oligopeptides / Q000235:genetics / Q000378:metabolism; D011518:Proto-Oncogene Proteins / Q000235:genetics / Q000378:metabolism; D012333:RNA, Messenger / Q000378:metabolism; D000075142:RUNX1 Translocation Partner 1 Protein; D011993:Recombinant Fusion Proteins / Q000235:genetics; D012475:Salmonella / Q000378:metabolism*; D014157:Transcription Factors / Q000235:genetics / Q000378:metabolism; D019444:Vaccines, DNA / Q000276:immunology*
chemical_list: D001428:Bacterial Vaccines; D058851:GPI-Linked Proteins; C110615:HA-1 antigen; D036341:Intercellular Signaling Peptides and Proteins; D035683:MicroRNAs; D015778:Minor Histocompatibility Antigens; C538984:Mirn182 microRNA, human; D009842:Oligopeptides; D011518:Proto-Oncogene Proteins; D012333:RNA, Messenger; D000075142:RUNX1 Translocation Partner 1 Protein; C082222:RUNX1T1 protein, human; D011993:Recombinant Fusion Proteins; D014157:Transcription Factors; C423230:ULBP2 protein, human; D019444:Vaccines, DNA; D007371:Interferon-gamma; D053804:Granzymes
keywords: DNA vaccine; NK cells; Salmonella; innate immunity